145 related articles for article (PubMed ID: 21897065)
21. Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
Moreau P; de Wit E
Br J Haematol; 2017 Oct; 179(2):198-218. PubMed ID: 28556890
[TBL] [Abstract][Full Text] [Related]
22. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
Palumbo A; Sonneveld P
Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
[TBL] [Abstract][Full Text] [Related]
23. Multiple myeloma: new uses for available agents, excitement for the future.
Anderson KC
J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):694-6. PubMed ID: 25995433
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.
Mian M; Pescosta N; Badiali S; Cappelletto PC; Marcheselli L; Luminari S; Patriarca F; Zambello R; Pascarella A; Tagariello G; Marabese A; Mondello P; Billio A; Cortelazzo S
Br J Haematol; 2019 Jun; 185(5):944-947. PubMed ID: 30478966
[No Abstract] [Full Text] [Related]
25. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
[TBL] [Abstract][Full Text] [Related]
26. The effect of novel therapies in high-molecular-risk multiple myeloma.
Lancman G; Tremblay D; Barley K; Barlogie B; Cho HJ; Jagannath S; Madduri D; Moshier E; Parekh S; Chari A
Clin Adv Hematol Oncol; 2017 Nov; 15(11):870-879. PubMed ID: 29200420
[TBL] [Abstract][Full Text] [Related]
27. [Molecular targeting therapy for multiple myeloma].
Takatoku M
Nihon Rinsho; 2007 Dec; 65(12):2345-50. PubMed ID: 18069281
[TBL] [Abstract][Full Text] [Related]
28. Bendamustine in the treatment of hematologic malignancies. Introduction.
Diehl V; Cheson BD
Semin Oncol; 2002 Aug; 29(4 Suppl 13):1-3. PubMed ID: 12170424
[No Abstract] [Full Text] [Related]
29. Tanespimycin as antitumor therapy.
Dimopoulos MA; Mitsiades CS; Anderson KC; Richardson PG
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):17-22. PubMed ID: 21454186
[TBL] [Abstract][Full Text] [Related]
30. Pomalidomide for multiple myeloma.
Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
[TBL] [Abstract][Full Text] [Related]
31. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
[TBL] [Abstract][Full Text] [Related]
32. Bendamustine in the treatment of multiple myeloma: results and future perspectives.
Pönisch W; Niederwieser D
Semin Oncol; 2002 Aug; 29(4 Suppl 13):23-6. PubMed ID: 12170429
[TBL] [Abstract][Full Text] [Related]
33. Phase I studies with bendamustine: an update.
Schrijvers D; Vermorken JB
Semin Oncol; 2002 Aug; 29(4 Suppl 13):15-8. PubMed ID: 12170427
[TBL] [Abstract][Full Text] [Related]
34. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
Highsmith KN; Chen SE; Horowitz S
Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
[TBL] [Abstract][Full Text] [Related]
35. Drugs: More shots on target.
Appel A
Nature; 2011 Dec; 480(7377):S40-2. PubMed ID: 22169800
[No Abstract] [Full Text] [Related]
36. An old drug with a new future: bendamustine in multiple myeloma.
Gentile M; Recchia AG; Mazzone C; Vigna E; Martino M; Morabito L; Lucia E; Bossio S; De Stefano L; Granata T; Palummo A; Morabito F
Expert Opin Pharmacother; 2013 Nov; 14(16):2263-80. PubMed ID: 24053161
[TBL] [Abstract][Full Text] [Related]
37. New drugs in multiple myeloma and the significance of autologous stem cell transplants.
Jagannath S
Clin Adv Hematol Oncol; 2009 Mar; 7(3):178-9. PubMed ID: 19398940
[No Abstract] [Full Text] [Related]
38. Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program.
Damaj G; Malard F; Hulin C; Caillot D; Garidi R; Royer B; Marit G; Stoppa AM; Banos A; Morineau N; Moreau P; Fitoussi O; Tiab M; Moreau P
Leuk Lymphoma; 2012 Apr; 53(4):632-4. PubMed ID: 21916831
[TBL] [Abstract][Full Text] [Related]
39. [Pomalidomide for multiple myeloma].
Dougé A; Lemal R; Chaleteix C
Bull Cancer; 2017 Sep; 104(9):707-713. PubMed ID: 28583668
[TBL] [Abstract][Full Text] [Related]
40. [Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine].
Furukawa Y; Hiraoka N; Wada T; Kikuchi J; Kano Y
Nihon Yakurigaku Zasshi; 2011 Jul; 138(1):26-32. PubMed ID: 21747206
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]